Source comparison
Sermorelin Help Thinning Hair: Protocol Design vs Evidence
Primary pathway Stimulates pituitary GH release → systemic IGF-1 elevation Indirect (no follicle-specific trials) Minoxidil: direct K+ channel opening in follicles (FDA-approved) Target cell receptors IGF-1 receptors on keratinocytes and dermal papilla cells P
This comparison does not assign a generated winner or score.
- Primary pathway
- Stimulates pituitary GH release → systemic IGF-1 elevation
- Indirect (no follicle-specific trials)
- Minoxidil: direct K+ channel opening in follicles (FDA-approved)
- Target cell receptors
- IGF-1 receptors on keratinocytes and dermal papilla cells
- Proven in vitro, unproven in vivo for hair
- Finasteride: blocks 5-alpha-reductase (proven DHT reduction)
- Typical dosing
- 200–500 mcg subcutaneous, 5–7x/week
- Not standardized for hair outcomes
- Minoxidil 5%: twice daily topical application
- Time to effect (if effective)
- Theoretical 3–6 months based on anagen cycle
- Unknown. No clinical endpoint data
- Minoxidil: visible improvement 4–6 months
- Mechanism specificity
- Systemic. Not follicle-targeted
- Low specificity for hair vs other tissues
- High specificity (topical minoxidil stays local)
- Clinical trial evidence
- None for hair loss as primary endpoint
- No randomized controlled trials
- Multiple Phase 3 trials with hair count data
- Bottom Line
- Plausible biological mechanism without clinical validation for hair-specific outcomes
- Sermorelin may support systemic tissue repair, but it's not a proven hair loss treatment. Evidence doesn't justify using it as a primary intervention for thinning hair